Team Toon Stilma CEO Toon Stilma CEO Toon is co-founder and CEO of XS Innovations. With over 25 years of experience in medical devices, consulting, and aerospace, he formerly led Roland Berger Tenzing, supporting entrepreneurs in scaling their ventures.
No named decision-maker yet.
Careers mailbox is known
Redefining Complement Therapies. Complement Therapeutics is a clinical-stage biotechnology company advancing precision therapies for complement-mediated diseases.
No named decision-maker yet.
Careers mailbox is known
Nov 26, 2025
New executive Complement Therapeutics Appoints Dr Muhammad Ali Memon FRCOphth, as Chief Medical Officer · complementtx.com
Brenig Therapeutics develops innovative small-molecule therapies for neurodegenerative diseases, including LRRK2 inhibitors targeting Parkinson’s disease.
No named decision-maker yet.
Careers mailbox is known
Oct 30, 2025
New executive Brenig Therapeutics Names Megan McGill as Chief Executive Officer · brenigther.com
Jul 22, 2024
Raised a round Series A $65M
Dec 4, 2023
Launched Brenig Therapeutics Unveils Superior Safety Profile of LRRK2 Inhibitor BT-0267 with Exceptional CSF/Plasma Ratio at Future of Parkinson's Disease Con… · brenigther.com
2021
Founded
Avidicure is developing dual agonistic avidity-engineered multifunctional antibodies, AVC-Boosters, as monotherapy for treatment of cancer.
No named decision-maker yet.
Careers mailbox is known
May 2, 2025
Raised a round Seed $50M · led by EQT Life Sciences · Pulse 2.0
At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
No named decision-maker yet.
No careers mailbox known
Apr 14
New executive Kivu Bioscience Appoints Mohit Trikha, Ph.D., as Chief Executive Officer · kivubioscience.com
Oct 28, 2024
Raised a round Series A $92M · led by Novo Holdings
targedbiopharmaceuticals.com
TGD001 Our Science & Innovation Therapeutic Areas Development Pipeline Scientific Publications What is TGD001? TGD001 is TargED’s innovative therapy in development for targeted clot breakdown: thrombolysis, localized at the site of thrombosis.
No named decision-maker yet.
No careers mailbox known
Dec 24, 2025
Raised a round Series A $23.2M · led by BioGeneration Ventures · Pulse 2.0
2020
Founded
A biotech company dedicated to developing transformative medicines for people with neurodegenerative diseases using cutting-edge science and technologies.
No named decision-maker yet.
Careers mailbox is known
2020
Founded
About VarmX OUR MISSION To revolutionize the treatment of severe bleeding through a fast, safe, and effective medicine VarmX's VMX-C001 is being developed to facilitate the fast, safe, and effective treatment of severe bleeds in patients that are taking Factor Xa DOACS.
No named decision-maker yet.
Careers mailbox is known
Sep 15
Recognition VarmX recognised with two prestigious industry award nominations · varmx.com
Jan 8
Partnership VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization · varmx.com
May 25, 2023
Raised a round Series B $32.4M
Mar 8, 2023
New executive VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer · DutchNews.nl
